Alicia M Fry Selected Research

Therapeutics

10/2021	Effectiveness of oseltamivir treatment on clinical failure in hospitalized patients with lower respiratory tract infection.
1/2021	Differentiating severe and non-severe lower respiratory tract illness in patients hospitalized with influenza: Development of the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale.
1/2018	A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections.
5/2016	Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
9/2014	Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season.
1/2012	Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alicia M Fry Research Topics

Disease

123	Human Influenza (Influenza) 03/2022 - 12/2006
40	Infections 03/2022 - 03/2009
12	COVID-19 11/2021 - 01/2020
11	Pneumonia (Pneumonitis) 07/2020 - 12/2002
6	Virus Diseases (Viral Diseases) 05/2016 - 01/2011
5	Fever (Fevers) 10/2021 - 04/2011
4	Respiratory Tract Infections (Respiratory Tract Infection) 10/2021 - 01/2018
4	Communicable Diseases (Infectious Diseases) 01/2019 - 11/2004
2	Egg Hypersensitivity (Egg Allergy) 01/2020 - 01/2018
2	Pharyngitis (Sore Throat) 01/2019 - 01/2018
2	Asthma (Bronchial Asthma) 01/2017 - 01/2013
2	Herpesviridae Infections (Herpesvirus Infection) 02/2014 - 03/2013
2	Trachoma 11/2004 - 02/2003
1	Anaphylaxis (Anaphylactic Shock) 01/2021
1	Hypersensitivity (Allergy) 01/2021
1	Breakthrough Infections 01/2021
1	Drug-Related Side Effects and Adverse Reactions 12/2020
1	Lung Diseases (Lung Disease) 07/2020
1	Frailty 01/2019
1	Rhinorrhea 01/2019
1	Bronchitis 01/2018
1	Sinusitis 01/2018
1	Poliomyelitis (Polio) 12/2017
1	Influenza in Birds (Avian Flu) 09/2017
1	Cough 05/2016
1	Body Weight (Weight, Body) 05/2015
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2013
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2013
1	Respiratory Insufficiency (Respiratory Failure) 04/2011
1	Vomiting 04/2011
1	Acquired Immunodeficiency Syndrome (AIDS) 03/2005
1	Pneumococcal Infections 12/2002

Drug/Important Bio-Agent (IBA)

57	VaccinesIBA 03/2022 - 12/2002
53	Influenza Vaccines (Influenza Vaccine)FDA Link 03/2022 - 03/2010
44	Antiviral Agents (Antivirals)IBA 03/2022 - 12/2009
26	Oseltamivir (Tamiflu)FDA Link 10/2021 - 03/2009
12	Neuraminidase (Sialidase)IBA 05/2016 - 03/2011
6	Pharmaceutical PreparationsIBA 05/2015 - 11/2004
5	COVID-19 VaccinesIBA 11/2021 - 12/2020
5	Hemagglutinins (Hemagglutinin)IBA 01/2021 - 12/2009
5	Anti-Bacterial Agents (Antibiotics)IBA 12/2020 - 02/2003
5	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020 - 11/2009
4	Messenger RNA (mRNA)IBA 11/2021 - 01/2021
4	mRNA VaccinesIBA 11/2021 - 01/2021
4	AntibodiesIBA 10/2021 - 01/2011
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 05/2016
2	2019-nCoV Vaccine mRNA-1273IBA 04/2021 - 01/2021
2	BNT162 VaccineIBA 04/2021 - 01/2021
2	Inactivated VaccinesIBA 01/2021 - 12/2018
2	Attenuated VaccinesIBA 01/2021 - 10/2017
2	FluMistIBA 06/2018 - 01/2017
2	AntigensIBA 10/2017 - 12/2002
2	Particulate MatterIBA 08/2017 - 05/2014
2	insulin receptor-related receptor (IRR)IBA 01/2017 - 12/2006
2	Dihydrotachysterol (AT 10)IBA 12/2013 - 12/2010
2	AdamantaneIBA 01/2011 - 11/2010
1	Complement System Proteins (Complement)IBA 11/2021
1	N 30IBA 10/2021
1	Viral RNAIBA 01/2021
1	Synthetic Vaccines (Recombinant Vaccines)IBA 01/2021
1	Combined VaccinesIBA 01/2021
1	EndonucleasesIBA 01/2019
1	baloxavirIBA 01/2019
1	CI 22IBA 01/2019
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019
1	FluLavalIBA 01/2017
1	AfluriaIBA 01/2017
1	FluBlokIBA 01/2017
1	NucleoproteinsIBA 05/2016
1	Zanamivir (Relenza)FDA Link 10/2015
1	Soaps (Soap)IBA 06/2015
1	oplunofuspIBA 08/2014
1	TinIBA 05/2014
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 01/2013
1	RNA (Ribonucleic Acid)IBA 04/2012
1	EnzymesIBA 04/2011
1	peramivirIBA 03/2011
1	MacrolidesIBA 02/2003
1	Azithromycin (Zithromax)FDA LinkGeneric 02/2003
1	Polysaccharides (Glycans)IBA 12/2002
1	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 12/2002

Therapy/Procedure

7	Contraindications 01/2021 - 01/2017
6	Therapeutics 10/2021 - 01/2012
5	Artificial Respiration (Mechanical Ventilation) 01/2021 - 03/2005
4	Ambulatory Care (Outpatient Care) 12/2020 - 09/2014
4	Chemoprevention 01/2019 - 01/2012
3	Length of Stay 10/2021 - 12/2005
2	Personal Protective Equipment 12/2020 - 01/2019
1	Hand Hygiene 12/2020
1	Activities of Daily Living (ADL) 07/2020
1	Long-Term Care 12/2009
1	Tracheostomy 03/2005